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Abstract
Background: The historic use of full-dose ritonavir as part of an unboosted protease inhibitor (PI)-based
antiretroviral therapy regimen in some South African children contributes to the frequent accumulation of major PI
resistance mutations.
Methods: In order to describe the prevalence of major PI resistance in children failing antiretroviral therapy and to
investigate the clinical, immunological and virological outcomes in children with PI resistance, we conducted a
cross-sectional study, with a nested case series, following up those children with major PI resistance. The setting
was public health sector antiretroviral clinics in the Western Cape province of South Africa, and the subjects were
children failing antiretroviral therapy. The following outcome measures were investigated: CD4 count, viral load and
resistance mutations.
Results: Fourteen (17%) of 82 patients, referred from tertiary hospitals, had major PI resistance. All these patients
were exposed to regimens that included ritonavir as a single PI. Immune reconstitution and clinical benefit were
achieved when using a lopinavir/ritonavir-based treatment regimen in these children with prior PI resistance. At first
HIV-1 viral load follow up after initial resistance testing (n = 11), only one patient had a viral load of less than 400
copies/ml; at a subsequent follow up (n = 9), the viral loads of five patients were less than 400 copies/ml. Patients
retained on LPV/r had lower viral loads than those switched to a non-nucleoside reverse transcriptase inhibitor
(NNRTI). However, two of three patients with follow-up resistance tests accumulated additional PI resistance.
Conclusions: In children with pre-existing PI resistance, although initially effective, the long-term durability of a
lopinavir/ritonavir-based treatment regimen can be compromised by the accumulation of resistance mutations.
Furthermore, a second-line NNRTI regimen is often not durable in these patients. As genotypic resistance testing
and third-line treatment regimens are costly and limited in availability, we propose eligibility criteria to identify
patients with high risk for resistance and guidance on drug selection for children who would benefit from third-
line therapy.
Background
In South Africa, antiretroviral therapy (ART) became
available for adults and children through public sector
programmes in 2004. Due to the use of nevirapine
(NVP), a non-nucleoside reverse transcriptase inhibitor
(NNRTI) for the prevention of mother to child trans-
mission (PMTCT), first-line therapy in children below
three years of age includes a protease inhibitor (PI) with
two nucleoside reverse transcriptase inhibitors (NRTIs).
The preferred PI is lopinavir/ritonavir (LPV/r), which
has a high genetic barrier to resistance development.
However, ritonavir (RTV) as a single PI (sPI) was initi-
ally used for infants below six months of age and also
when rifampicin was needed for co-treatment of tuber-
culosis, or in some children receiving therapy before the
national roll-out guidelines were formulated. The cor-
rect dosage for LPV/r in infants below six months of
age was established only in 2007 and the boosting of
LPV/r with additional RTV when using rifampicin in
2008 [1,2]. Until then, many children were therefore
treated with RTV sPI.
We previously documented in children with detectable
viral loads that those on RTV sPI were more likely to
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did not observe any mutation accumulation in patients
while on LPV/r therapy; however, we had limited follow
up of patients with prior PI resistance that had detect-
able viral loads on LPV/r therapy. We therefore present
outcomes in a case series of 14 RTV sPI-exposed chil-
dren with significant PI resistance to further explore the
durability of LPV/r therapy after sPI exposure.
Methods
We conducted a cross-sectional study, with a nested fol-
low-up case series of those children with major PI resis-
tance. Specimens were received from patients for
genotypic resistance testing (GRT) from Tygerberg and
Red Cross Children’s Hospitals and other antiretroviral
treatment sites in the Cape Town Metropole in the
Western Cape province of South Africa. Specimens
were collected from January 2007 to November 2009.
Patient caregivers (parent or legal guardian) gave writ-
ten informed consent (and minors assented) as part of
an observational study of antiretroviral resistance. Inclu-
sion criteria for GRT were: an available ART history,
detectable viral loads (>400 copies/ml, defined by the
sensitivity of our test), and recent adequate adherence,
as documented by the referring clinician (previous poor
adherence did not exclude patients). Viral load testing
was with the NucliSens EasyQ system (BioMerieux, Box-
tel, The Netherlands). GRT was done by a well-validated
“in-house” method for viral RNA, extracted from
plasma, followed by reverse transcriptase polymerase
chain reaction and bulk automated sequencing [3,4].
Clinical data were recorded in a secure database. Fol-
low-up testing included six-monthly CD4 and viral load
counts. We used the geometric mean to indicate central
tendency for viral load values, which are not normally
distributed. Sequences were imported into the following
four resistance interpretation systems (RIS): 1) The
Stanford HIVDB v. 6.0.11; 2) Rega v.8.0.2; 3) French
ANRS v. 2011.20 accessed through the Stanford Data-
base HIVAlg programme (available from: http://sierra2.
stanford.edu/sierra/servlet/JSierra?action=hivalgs), the
RegaDB Software, HIV Data Management and Analysis
Environment Clinical Edition (available from: http://
newbioafrica.mrc.ac.za:8080/regadb-ui/RegaDB); and 4)
Geno2Pheno (available from http://www.geno2pheno.
org). The Committee for Human Research at Stellen-
bosch University approved the study.
Results
Description of specimens received for genotypic
resistance testing
Of 97 specimens, the protease gene was sequenced in 88
specimens from 82 patients. The gene could not be
amplified or sequenced in nine. Seventy-seven patients
had a single specimen each, four patients contributed
two specimens each, and one patient had three speci-
mens. We also recorded prior PI therapy and therapy at
the time of resistance testing in these patients (Table 1).
Patients with major PI resistance mutations
Fourteen of 82 patients (17%) had major PI resistance
[Genbank: JN087531-JN087547], all of whom were
exposed to RTV as a single PI. In these patients, major
PI mutations (frequency) were: V33F (n = 3), M46I (n =
4), I54V (n = 13), L76V (n = 2), V82A/M/S (n = 13)
and L90M (n = 4). Minor PI mutations were: L10FIV (n
= 8), L23I (n = 1), L24I (n = 2), K43T (n = 1) and Q58E
(n = 2). Common subtype C polymorphisms were: T74S
(n = 3) and L89M (n = 7). When the HIVDB “sensitive”,
“intermediate” or “resistant” classification is used (which
does not include the standard HIVDB “low-level” and
“potential low-level” categories), 13 of 14 patients had at
least intermediate resistance to LPV/r and atazanvir/
ritonavir (ATV/r), five to tipranivir/ritonavir (TPV/r)
and only two to darunavir/ritonavir (DRV/r).
In contrast, none of 30 patients treated only with
LPV/r as the PI component of their regimens had major
PI mutations. Detailed antiretroviral therapy and resis-
tance information for patients with PI resistance are
provided in Table 2. The median age of patients with
major PI resistance mutations was 36 (interquartile
r a n g e[ I Q R ] :4 3 - 5 8 )m o n t h s .T h em e d i a nd u r a t i o no f
R T Vt h e r a p yw a s1 6 . 8( I Q R :1 1 . 6 - 2 6 . 3 )m o n t h s .F o r
Table 1 Protease inhibitor exposure and current therapy
details of the 82 patients (88 resistance tests)
Prior PI exposure PI or NNRTI component at the time
of resistance testing
PI (n = 53) LPV/r
(n = 30)
LPV/r (n = 30)
RTV
(n = 23)
LPV/r (n = 16)
LPV/r+ NVP (n = 1)
EFV (n = 4)
RTV (n = 2)
No PI
(n = 29)
EFV (n = 17)
NVP (n = 11)
EFV or NVP at different time points(n = 1)
PI: Protease inhibitor




At testing, 53 patients had PI exposure. Of these, 47 were treated with PIs (45
with LPV/r and 2 with RTV) and 5 with EFV and 1 with LPV/r plus NVP.
Twenty-nine without PI exposure were treated with NNRTIs (17 with EFV, 12
with NVP and one with either NVP or EFV at different time points). Twenty-
three patients had received RTV sPI, of whom16 had been switched to LPV/r
and one to NVP plus LPV/r. Four were switched to EFV and two remained on
RTV at the time specimens were submitted.
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Study no Prior Rx Current Rx PI resistance TAMS LPV/r resistance interpretation HIVDB: resistance
to salvage PIs
Rega HIVDB ANRS Geno2Pheno DRV/r TPV/r ATV/r
138 AZT, 3TC, RTV AZT, 3TC, LPV/r M46I, I54V, V82A, L10F None Int Int Int Int None None Int
344 AZT, 3TC, RTV D4T, ABC, LPV/r L10V, L24I, K43T, M46I, I54V, T74S, V82A M41L, D67N, K70R, T215F, K219Q Res Int Res Res None Pot low Int
345 D4T, 3TC, RTV AZT, 3TC, EFV L10I, I54V, V82A D67N, K70R, T215FY, K219EQ Int Int Int Int None None Low
87 D4T, 3TC, RTV AZT, 3TC, RTV I54V, V82A, L10V, L33F None Int Int Int Int None Low Int
34 D4T, 3TC, RTV D4T, 3TC, RTV I54V; V82A; L10V None Int Int Int Sens None None Low
34b D4T, 3TC, LPV/r I54V; L76V; V82A; L10I, A71V None Res Res Res Int Low None Low
78 AZT, 3TC, RTV ABC, DDI, NVP L33F, I54V, A71V, V82S, L90M D67N, K70R, K219E Int Int Res Int None Int Int
78b AZT, 3TC, LPV/r L33F, I54V, A71V, V82S, L90M D67N, K70R, T215I, K219E Int Int Res Int None Int Int
228 AZT, 3TC, RTV AZT, DDI, LPV/r L10V, L23I, M46I, I54V, L76V, V82M D67N, K70R, T215F, K219E Res Int Res Res Low None Int
185 D4T, DDI, RTV AZT, 3TC, EFV V82A None Sens Int Sens Sens None None Low
32 D4T, 3TC, RTV D4T, 3TC, LPV/r I54V, V82A, L10I, T74S None Int Int Res Int None None Low
32b D4T, 3TC, LPV/r L10FI, L33F, I54V, T74S, V82A None Int Int Res Int None Low Int
94 D4T, 3TC, RTV D4T, 3TC, LPV/r M46I, I54V, V82A, L10F, L24I None Int Int Res Res None None Int
29 AZT, 3TC, RTV AZT, 3TC, LPV/r I54V None Sens Sens Sens Sens None None Pot low
38 D4T, DDI, RTV D4T, 3TC, LPV/r I54V; V82A; L90M; Q58E; A71V None Int Int Res Int None Low Int
324 D4T, 3TC, RTV D4T, 3TC, LPV/r M46V, I54V, A71V, T74S,V82A, L90M None Int Int Res Res None None Int
49 D4T, DDI, RTV D4T, DDI, RTV I54V; V82A; L90M; L33F; Q58E M41L; D67N; T215Y Int Int Int Sens None Low Int
Rega: Rega v.8.0.2 resistance interpretation system
HIVDB: The Stanford HIV Data Base v. 6.0.11 resistance interpretation system
ANRS: The French ANRS v. 2011.20 resistance interpretation system
Geno2Pheno: The Geno2Pheno resistance interpretation system
For comparison of resistance interpretation systems, the “Sensitive, Intermediate and Resistant” (SIR) classification was used: Sens: Sensitive (high-level resistant), Int: Intermediate-level resistance, and Res: Resistant
The standard HIVDB classification includes additional categories: Low: Low-level resistance, Pot low: Potential low-level resistance
Prior Rx: Prior treatment
Current Rx: Treatment at the time of resistance test
TAMS: Thymidine-associated mutations
All patients receiving 3TC at the time of resistance testing had the M184V mutation.
All patients included in the table had HIV-1 genotype C pol sequences according to the Rega HIV-1 subtyping tool.










































































































8those given subsequent LPV/r therapy, the median dura-
tion of LPV/r therapy was 15.9 (IQR: 6.3-39.8) months.
Patients who received LPV/r without prior RTV expo-
sure received LPV/r for a median of 14.5 (IQR: 9-24.4)
months. At the time of resistance testing, nine were
treated with LPV/r, three with RTV, two with efavirenz
(EFV) and one with NVP. Six had received NVP as part
of PMTCT, two did not receive PMTCT and in six,
PMTCT history was unknown.
The M184V mutation, conferring resistance to lamivu-
dine (3TC), was detected in all 14 specimens from 11
patients failing 3TC-containing therapy with major PI
resistance. At the time of resistance testing, six of 12
with viral load data had values between 1000 and 5000
(5000 is the current recommendation for therapy
switching in South Africa). Five patients had three or
more thymidine analogue mutations (TAMs), in addi-
tion to significant PI mutations. Four of the 14 had
intermediate to high-level EFV and NVP resistance.
Eleven patients were followed up after initial resis-
tance testing. Initially, only one suppressed to less than
400 copies/ml. Subsequently, five of nine suppressed to
less than 400 copies/ml (Table 3). Only two of five chil-
dren continuing on an NNRTI regimen had TAMs, but
none had virological suppression and were therefore at
high risk for developing NNRTI resistance.
Three of six patients who continued on LPV/r had
TAMs, Nevertheless, patients who continued on LPV/r
achieved lower viral loads than those on an NNRTI. Of
the 11 patients followed up, four patients had three-
class (PI, NRTI and NNRTI) resistance compromising
future therapy options.
Three patients (all with at least intermediate resistance
to LPV/r according to Stanford interpretation) had fol-
low-up resistance tests: in two, three additional PI muta-
tions accumulated over 379 days (patient 34) and two
additional PI mutations in 498 days (patient 32) while
treated with LPV/r. The third patient (patient 78) accu-
mulated no additional PI mutations in a year, between
tests, receiving an NVP- based regimen for the first
month and an LPV/r regimen for the remainder. Despite
acquiring an additional TAM, he maintained low-level
viraemia, the CD4 percentage improving from 19.9% to
37.6%. Therapeutic drug monitoring found that LPV
levels were inadequate. After improved adherence and
dose adjustment, the patient had one undetectable viral
load, later followed by a recurrence of failure. Apart
from pre-existing neuro-developmental delay, he devel-
oped no new HIV-related conditions.
Table 3 summarizes the plasma HIV RNA levels and
CD4 percentage follow-up tests after resistance testing,
categorized by whether patients continued on an
NNRTI regimen (EFV) or LPV/r.
Discussion
Monitoring and treatment in South Africa
Responding to antiretroviral failure and selecting an
optimal regimen is very context specific. In South
Africa, viral load monitoring is routinely available, but
with only very limited access to antiretroviral resistance
testing and with only two lines of therapy for children.
In infants exposed to nevirapine, through a PMTCT
intervention, there may effectively be only one regimen.
In young sub-Saharan African children, who often start
Table 3 Follow up CD4% and HIV-1 viral load after detecting major PI
Patients who continued on an
NNRTI regimen
CD4% range (mean CD4%); number
(n) of patients
HIV-1 VL range (geometric mean of detectableVL) in IU/ml;
number (n) of patients
Baseline* 19.9 - 49.6 (32.2); n = 5 2300-47,000 (15,804); n = 5
First follow up 23.2-39.7 (30.8); n = 5 9400-25,000 (14,397); n = 5
Second follow up 22.9-46.4 (32.4); n = 5 700-38,000 (5504); n = 4
Patients who continued on an
LPV/r regimen
Baseline* 29.4-39.9 (34.6); n = 5 1000-34,000 (3898); n = 6
First follow up 25.6-36.6 (32.4); n = 5 1 × LDL, remainder 1800-38,000 (7473); n = 6
Second follow up 27.2-40.8 (35.6); n = 5 1 × LDL, remainder 320-390 (355); n = 5
Total: All patients
Baseline* 17.1-49.6 (31.9); n = 11 1000-47,000 (6450); n = 12
First follow up 23.2-39.7 (31.4); n = 11 1 × LDL, remainder 1800-38,000
(9558); n = 11
Second follow up 22.9-46.4 (33.1); n = 11 1 × LDL, remainder 320-38,000 (1794); n = 9
VL: Viral load
*Baseline: Refers to values at the time of the first resistance test that resulted in a decision to either continue a PI regimen or switch to an NNRTI regimen
First follow up: Approximately six months after baseline
Second follow up: Approximately 12 months after baseline
LDL: Lower than detection limit (of 357 copies/ml)
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to suppress viral loads than a boosted PI regimen [5],
and in a recent multicentre study, P1060, an NVP regi-
men has been shown to be inferior to an LPV/r regimen
both in children exposed to NVP through PMTCT [6]
and in those unexposed [7].
Furthermore, children who were switched, when viro-
logically suppressed from LPV/r to NVP were more
likely to have viral loads of more than 1000 copies per
ml and harbour resistance than those retained on LPV/r
[8]. This is in contrast to the multi-centre PENPACT-1
study where outcomes for PI and NNRTI regimens were
similar; however, the median age was 6.5 years (much
older than in P1060), and in 48%, the PI prescribed was
nelfinavir, which has a lower genetic barrier than LPV/r.
Detected protease inhibitor resistance
We found that 14 out of 23 children with historic expo-
sure to a regimen that included RTV sPI had major PI
resistance, whereas none of 30 given LPV/r had major
PI resistance. Nevertheless, it is not known if RTV sPI
exposure per se was aetiological in selecting for PI resis-
tance, in all cases, as other factors, such as longer ther-
apy duration[3] and concomitant rifampicin use, could
have contributed to PI resistance. The high prevalence
of major PI resistance mutations (14 out of 82 or 17%)
in this study cannot be extrapolated to the population
as a whole as most of these specimens were referred
from tertiary hospitals. However, this may represent a
typical setting, which takes ca r eo fp a e d i a t r i cp a t i e n t s
with long-term failure.
As we did not observe any PI resistance, despite hav-
ing detectable viral loads, in nine of the 23 patients trea-
ted with LPV/r and prior RTV sPI treatment, and 30
out of 30 without prior RTV sPI, their virological failure
was most likely due to poor adherence or inadequate
dosage. This concurs with a French study that found a
very low rate of PI resistance in children initiated on
LPV/r despite a high prevalence of virologic failure [9].
Three patients (patients 32, 334 and 344) harboured
T74S, a common HIV-1 subtype C protease polymorph-
ism, which is found in higher frequencies in patients
treated with PIs, especially nelfinavir. It has been
reported to possibly restore fitness in patients with mul-
tiple PI resistance and to increase susceptibility to rito-
navir and indinavir [10].
Detected NRTI resistance mutations
Once major PI resistance was present, as expected, all
children on lamivudine (3TC) had the M184V mutation.
3TC has a low genetic barrier and M184V occurs early
during true drug failure [11,12]. A high prevalence of
M184V has been reported in other studies in children
from sub-Saharan Africa [13-15]. Nevertheless, 3TC is
still preferred as a component of first-line therapy and
often retained in second-line regimens for the following
reasons: it has excellent tolerability and M184V
increases susceptibility towards other NRTI compo-
nents, such as AZT, D4T or tenofovir (TDF). Further-
more it reduces viral fitness, slows the accumulation of
TAMs [12,16,17] and may have clinical and immunolo-
gical benefit [18].
Outcomes after detecting PI resistance
Patients who continued on an LPV/r regimen had a bet-
ter virological response than those switched to an
NNRTI regimen. However, in two of three patients, who
were switched to LPV/r after RTV sPI, additional muta-
tions were observed in their second specimens, increas-
ing PI resistance, thus questioning the durability of
LPV/r therapy. However, despite significant PI resistance
in 12, with additional TAMs in five children, there was
no immunologic deterioration and viral loads remained
relatively low in the majority.
This may be due to residual efficacy of the antiretro-
viral drugs (especially LPV/r), especially at increased
plasma levels [19] and the reduced fitness (crippling
effect) of some resistance mutations, such as M184V,
and some PI resistance mutations. Nevertheless, children
require ART for life. Inadequate response to therapy
may have developmental and neurological consequences
and could seriously compromise quality of life. Non-
suppressive antiretroviral therapy may in the long run
compromise future therapy options through the accu-
mulation of resistance mutations, despite intermediate-
term immunological and clinical benefits.
Criteria for genotypic resistance testing
The use of RTV sPI in children contributed to a cohort
with an increased risk of PI resistance and therapy fail-
ure [20]. Although children who never received an
unboosted PI may also develop PI resistance, the current
risk is probably too low to include this in criteria for
genotypic resistance testing for resource-limited settings.
A good adherence history, in combination with random
LPV plasma concentration measurement (which cost
only about US$40 in the South African state sector),
may exclude patients with very poor adherence from
unnecessary GRT, which is more expensive (about US
$300 for in-house testing through the National Health
Laboratory Service, the public laboratory service provi-
der in South Africa).
An adequate plasma lopinavir concentration does not
exclude periods of poor adherence as ingesting few
doses before phlebotomy could result in adequate con-
centrations. However, a low level is indicative of poor
adherence. Such random testing has been shown to be
valuable in South African adults on second-line therapy
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to facilitate dose adjustment and achieve virological sup-
pression. An additional surrogate for adherence is
macrocytosis in patients on either zidovudine or stavu-
dine [22,23].
Due to the reduced fitness of some resistant viruses, a
high percentage of children with PI resistance may have
relative low viral loads, as seen by the number with viral
loads below 5000 copies/ml. Therefore, 1000 copies/ml
may be an appropriate cut off for resistance testing in
patients with a high pre-test probability of protease
resistance (such as prior exposure to an RTV sPI ART
regimen). Therefore, we recommend using 1000 copies/
ml, rather than 5000 copies, as suggested by the World
Health Organization, for those who might benefit from
resistance testing.
Defining criteria for third-line therapy
Children who are switched to an NNRTI regimen at the
time of PI failure are likely to have an increased risk of
failure and resistance, due to the low genetic barrier of
the regimen, previous exposure to NVP for PMTCT,
and probable sub-optimal adherence. Furthermore,
those failing a PI regimen, but with NRTI resistance
(such as TAMs) are unlikely to achieve full virological
suppression on a second-line NNRTI regimen, and thus
rapidly acquire NNRTI resistance. There is therefore a
need for a durable third-line combination. However,
third-line therapy for children not responding to the
currently available regimens is more costly than stan-
dard first- or second-line therapy. Therefore, defining
indications for third-line therapy in a cost-effective man-
ner is essential.
Two candidate PIs for salvage are TPV/r and DRV/r.
Proposed criteria for GRT and third-line ART regimens
in children in a resource-limited setting are provided
here:
Criteria for paediatric genotype resistance testing (GRT)
Criteria A and B must be met
A) Failure of LPV/r regimen (two sequential viral
loads >1000 copies/ml, despite confirmed adherence
of >90%) while LPV drug levels are within the thera-
peutic range.
B) Prior exposure to an unboosted sPI regimen, such
as RTV.
Criteria for third-line ART regimens following GRT
Criteria A AND (B OR C) must be met
A) Susceptible or low-level resistance to the pro-
posed high barrier salvage PI (DRV/r or TPV/r) by
the Stanford HIVDB RIS.
B) Intermediate resistance to LPV/r (including either
Rega, HIVDB, ANRS or Geno2Pheno) with three or
more TAMs.
C) High-level LPV/r resistance (including either
Rega, HIVDB, ANRS or Geno2Pheno).
Selecting a third-line regimen
Although continuing therapy without virological sup-
pression is likely to result in additional resistance accu-
mulation, stopping antiretroviral therapy causes rapid
clinical and immunological deterioration [24]. In select-
ing an optimal third-line regimen, a balance between
tolerability, residual activity, fitness benefit and the resis-
tance threshold of a regimen should be sought. Where
possible, there should be at least good susceptibility (no
more than low-level resistance) to two of a three-drug
regimen. The most essential component is a PI with a
high barrier to resistance, such as DRV/r or TPV/r. The
choice is guided by the resistance pattern and the age of
the patient. TPV/r is available in a liquid formulation
for children as young as two years, whereas DRV/r is
only available in tablets for children older than six years.
DRV has a better side-effect profile than TPV.
Therapy history and genotypic resistance testing
should guide the choice of the best NRTI backbone.
When the selective pressure of a particular drug is
removed, resistance may become undetectable, but
remains clinically relevant. Almost all who previously
failed a regimen including 3TC have the M184V muta-
tion irrespective of the current genotypic result. TAMs
and other NRTI resistance mutations, such as K65R,
L74V and multiple NRTI resistance mutations, are espe-
cially valuable in determining the best NRTI backbone.
Quite often, in the presence of TAMs, tenofovir (TDF)
is the only NRTI with full susceptibility. However, there
is no formulation for patients who weigh less than 30kg.
Didanosine (DDI) often shows susceptibility. However,
its poor tolerability could contribute to a high failure
rate.
Even when the genotype suggests combining DDI and
abacavir (ABC), one should consider that resistance to
both drugs are conferred by the same mutations (L74V
and K65R), thus potentiating rapid failure. Rarely, sus-
ceptibility to all NRTIs is lost, necessitating the use of
other drugs classes in combination with DRV/r or TPV/
r. 3TC could be retained despite resistance, as we have
discussed. Other valuable salvage drugs, such as the
integrase inhibitor, raltegravir, the second-generation
NNRTI, etravirine, and the CCR5 inhibitor, maraviroc,
are not yet licensed for children.
Recent data has shown that raltegravir is valuable in
paediatric treatment [25]. When raltegravir is used in
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barrier, the proposed regimen must be able to achieve
full virological suppression. It should therefore combine
potent and high genetic barrier drugs, such as DRV/r or
TPV/r. The same applies to etravirine, especially with
prior exposure to NNRTIs. However, the addition of ral-
tegravir or etravirine may double the cost of the regi-
men. A practical approach is to combine a high-barrier
PI (DRV/r or TPV/r) with at least one other drug with
full sensitivity and a third with some beneficial effect
(such as 3TC). Expedited viral load testing should occur
within two to three months.
Successful third-line therapy of paediatric patients is
hindered by the lack of paediatric formulations and high
costs, with dosing especially problematic for children
younger than six years, largely a result of the low prior-
ity that is given globally to the development of paedia-
tric formulations and regimens [26]. 3TC monotherapy
and other sub-optimal interim measures, although being
used in some resource-limited settings, are not evidence
based, whereas continued PI therapy, even when it does
not achieve virological success, could nevertheless ren-
der immunological and clinical benefit in children [27],
but at the potential cost of resistance accumulation.
Conclusions
The historic use of an unboosted PI regimen contribu-
ted to a cohort of children at increased risk of having
compromised first- and second-line antiretroviral regi-
m e n s .T h e r e f o r e ,t h e r ei sa nu r g e n tn e e df o ra f f o r d a b l e
access to third-line drugs for children in lower- to mid-
dle-income countries. Furthermore, there is a need to
develop criteria to identify those in whom genotypic
antiretroviral resistance testing could assist in decision
making.
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